FINWIRES · TerminalLIVE
FINWIRES

ブラックアイアン社、生命保険の募集規模を拡大し、最大190万米ドルの収益を確保

-- ブラックアイアン(BKI.TO)は水曜日、2026年4月6日に発表した上場企業向け資金調達免除(LIFE)による株式発行の規模を20万米ドル増額し、当初の最大調達額170万米ドルから最大調達額190万米ドル(約260万カナダドル)に引き上げたと発表した。 同社によると、LIFEによる株式発行は引き続き仲介業者を介さずに実施され、発行価格は1ユニットあたり0.10カナダドル。今回の増額により、最大約260万ユニットが追加発行され、全額応募された場合、LIFEによる株式発行の最大発行ユニット数は約2,620万ユニットとなる。 また、各ユニットは、同社の普通株式1株(即時取引可能)と普通株式購入権1個で構成されると説明した。各ワラントは、クロージング日から60日後の日から36ヶ月間、保有者に当社普通株式1株を1株あたり0.20カナダドルの価格で購入する権利を付与します。ただし、特定の状況下では権利行使期間が短縮される場合があります。 当社は、調達資金は、シャイマニフスキー・プロジェクトに関連する許認可の更新を含む継続的なプロジェクト費用および管理費用、ならびに一般的な企業目的および運転資金に充当されると述べています。 さらに、本募集の完了は、トロント証券取引所の承認を含む、必要なすべての規制当局およびその他の承認の取得、ならびに最低約120万米ドルの総収入でのクロージングなど、特定の条件を満たすことを前提としています。

Related Articles

Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of The Hartford Insurance Group, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $8 to $155, valuing HIG shares at 11.3x our 2026 operating EPS estimate of $13.75 (cut by $0.45) and at 10.6x our 2027 EPS estimate of $14.65 (cut by $0.30), vs. the shares' one-year average forward multiple of 10.3x and peer average of 13x. Q1 EPS of $3.09 vs. $2.20 a year ago missed our $3.60 estimate and $3.39 consensus view. Operating revenue growth of 6.2% was in line with our 6%-10% forecast, amid 5.3% earned premium growth, 13% higher net investment income, and 7.9% fee revenue growth. Q1 written premium growth of 4% and full-year 2025 growth of 7% bode well for 2026 revenue trends as premiums are earned. Underwriting results improved significantly, with Personal Lines combined ratio improving to 87.7% from 106.1% and underlying combined ratio to 85.0% from 89.7%. Business Insurance combined ratio was stable at 94.8%. Weighing the Q1 EPS miss with HIG's decent top-line growth and discounted valuation to peers, we view the shares as undervalued.

$HIG
Research

Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Baker Hughes

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $14 to $82, reflecting a combination of our sum-of-the-parts (SOTP) and DCF models. For our SOTP model, we presume the oilfield services business (about 50% of BKR's franchise) to be valued at about 10x projected 2027 EBITDA (in line with major peers) and its industrial energy technology business (the other 50%) valued at 14x projected 2027 EBITDA (in line with the peer median). This blended approach, yielding a 12x multiple, implies a value of $73 per share. Meanwhile, our DCF model, using medium-term free cash flow growth of 5% per year, terminal growth of 2.5%, discounted at a WACC of 6.3%, yields intrinsic value of $91 per share. We cut our 2026 EPS estimate by $0.47 to $2.48, but we raise 2027's by $0.07 to $3.24. We acknowledge that the oilfield services business is likely to struggle in 2026 owing to the U.S.-Iran conflict, but the IET business appears quite robust and likely to be a source of both accelerating revenue growth and margins.

$BKR
Research

Research Alert: CFRA Maintains Hold Opinion In Shares Of Wab

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $285 from $275 following WAB's Q1 earnings print, valuing shares at 24.2x our 2027 EPS outlook of $11.76 (revised from $11.46; 2026 EPS estimate up to $10.57 from $10.50), a slight premium to WAB's long-term historical multiple average given structural improvements in earnings quality. While we are cautious on signs of overcapacity in the freight market, an elevated order backlog (12-month sits at over $9 billion), internal initiatives to shore up margins, and potential synergies from M&A activity positions WAB to continue growing earnings at double-digit rates in 2026-2027, in our view. Despite tariff-related cost pressures, WAB has done a commendable job of defending margins via a mix of pricing, lean manufacturing, and pruning of lower-profit operations. Q1 results were mixed but overall positive, in our view. We maintain our Hold recommendation on shares.

$WAB